The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment—Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients
Abstract
Purpose: The European Intergroup Cooperative Ewing's Sarcoma Study investigated whether cyclophosphamide has a similar efficacy as ifosfamide in standard-risk (SR) patients and whether the addition of etoposide improves survival in high-risk (HR) patients. Patients and Methods: SR patients (localized tumors, volume <100 mL) were randomly assigned to receive four courses of vincristine, dactinomycin, ifosfamide, and doxorubicin (VAIA) induction therapy followed by 10 courses of either VAIA or vincristine, dactinomycin, cyclophosphamide, and doxorubicin (VACA; cyclophosphamide replacing ifosfamide). HR patients (volume ≥100 mL or metastases) were randomly assigned to receive 14 courses of either VAIA or VAIA plus etoposide (EVAIA). Outcome measures were event-free survival (EFS; defined as the time to first recurrence, progression, second malignancy, or death) and overall survival (OS). Results: A total of 647 patients were randomly assigned: 79 SR patients were assigned to VAIA, 76 SR patients were assigned to VACA, 240 HR were assigned to VAIA, and 252 HR patients were assigned to EVAIA. The median follow-up was 8.5 years. In the SR group, the hazard ratios (VACA v VAIA) for EFS and OS were 0.91 (95% CI, 0.55 to 1.53) and 1.08 (95% CI, 0.58 to 2.03), respectively. There was a higher incidence of hematologic toxicities in the VACA arm. In the HR group, the EFS and OS hazard ratios (EVAIA v VAIA) indicated a 17% reduction in the risk of an event (95% CI, −35% to 5%; P = .12) and 15% reduction in dying (95% CI, −34% to 10%), respectively. The effect seemed greater among patients without metastases (hazard ratio = 0.79; P = .16) than among those with metastases (hazard ratio = 0.96; P = .84). Conclusion: Cyclophosphamide seemed to have a similar effect on EFS and OS as ifosfamide in SR patients but was associated with increased toxicity. In HR patients, the addition of etoposide seemed to be beneficial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modelling for Survival Data in Medical Research
(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,145
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Grier, H. E., Krailo, M. D., Tarbell, N. J., Link, M. P., Fryer, C. J. H., Pritchard, D. J., Gebhardt, M. C., Dickman, P. S., Perlman, E. J., Meyers, P. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020890 · Cited by 1,328
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,021
Ewing, J. (1972) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.22.2.95 · Cited by 583
Nesbit, M. E., Gehan, E. A., Burgert, E. O., Vietti, T. J., Cangir, A., Tefft, M., Evans, R., Thomas, P., Askin, F. B., & Kissane, J. M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.10.1664 · Cited by 570
Localized Ewing Tumor of Bone: Final Results of the Cooperative Ewing’s Sarcoma Study CESS 86
Paulussen, M., Ahrens, S., Dunst, J., Winkelmann, W., Exner, G. U., Kotz, R., Amann, G., Dockhorn-Dworniczak, B., Harms, D., Müller-Weihrich, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1818 · Cited by 445
Self-citationJürgens, H., Exner, U., Gadner, H., Harms, D., Michaelis, J., Sauer, R., Treuner, J., Voûte, T., Winkelmann, W., Winkler, K., et al. (1988) · Cancer · doi:10.1002/1097-0142(19880101)61:1<23::aid-cncr2820610106>3.0.co;2-m · Cited by 417
Self-citationJuergens, C., Weston, C., Lewis, I., Whelan, J., Paulussen, M., Oberlin, O., Michon, J., Zoubek, A., Juergens, H., & Craft, A. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20820 · Cited by 282
Self-citationMorphological grades of regression in osteosarcoma after polychemotherapy ? Study COSS 80
Salzer-Kuntschik, M., Delling, G., Beron, G., & Sigmund, R. (1983) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00625047 · Cited by 265
Cited by
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration
Gaspar, N., Hawkins, D. S., Dirksen, U., Lewis, I. J., Ferrari, S., Le Deley, M.-C., Kovar, H., Grimer, R., Whelan, J., Claude, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5256 · Cited by 722
Self-citationBone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hogendoorn, P. C. W., Athanasou, N., Bielack, S., De Alava, E., Dei Tos, A. P., Ferrari, S., Gelderblom, H., Grimer, R., Sundby Hall, K., Hassan, B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 718
Self-citationBalamuth, N. J., & Womer, R. B. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70286-4 · Cited by 686
Casali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Self-citationRisk of recurrence and survival after relapse in patients with Ewing sarcoma
Stahl, M., Ranft, A., Paulussen, M., Bölling, T., Vieth, V., Bielack, S., Görtitz, I., Braun‐Munzinger, G., Hardes, J., Jürgens, H., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23040 · Cited by 315
Self-citation
Metadata
- Authors
- Paulussen, M., Craft, A. W., Lewis, I., Hackshaw, A., Douglas, C., Dunst, J., Schuck, A., Winkelmann, W., Köhler, G., Poremba, C., Zoubek, A., Ladenstein, R., van den Berg, H., Hunold, A., Cassoni, A., Spooner, D., Grimer, R., Whelan, J., McTiernan, A., & Jürgens, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-09-20
- Volume
- 26
- Issue
- 27
- Pages
- 4385-4393
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2067019974
- Cited by
- 263
- References
- 18
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment—Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients. https://app.cochat.ai/papers/10.1200/jco.2008.16.5720
- The paper
- Paulussen, M., Craft, A. W., Lewis, I., Hackshaw, A., Douglas, C., Dunst, J., Schuck, A., Winkelmann, W., Köhler, G., Poremba, C., Zoubek, A., Ladenstein, R., van den Berg, H., Hunold, A., Cassoni, A., Spooner, D., Grimer, R., Whelan, J., McTiernan, A., & Jürgens, H. (2008). Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment—Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.16.5720
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.